Randomized Trials in Melanoma: An Update

Alexander M.M. Eggermont

doi:10.1016/j.soc.2005.12.001

Randomized Trials in Melanoma: An Update

Alexander M.M. Eggermont

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

17 Citaten (Scopus)

Samenvatting

No effective therapy for metastatic melanoma exists. Polychemotherapy or chemoimmunotherapy have not shown survival benefits. Vaccines have shown little activity in stage IV disease. To advance the identification of effective agents, new drugs can and should be offered as first-line treatment. Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs.

Originele taal-2	Engels
Pagina's (van-tot)	439-451
Aantal pagina's	13
Tijdschrift	Surgical Oncology Clinics of North America
Volume	15
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.1016/j.soc.2005.12.001
Status	Gepubliceerd - apr. 2006
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.soc.2005.12.001

Citeer dit

@article{3102b51ded3c4b68885594e554c4fc78,

title = "Randomized Trials in Melanoma: An Update",

abstract = "No effective therapy for metastatic melanoma exists. Polychemotherapy or chemoimmunotherapy have not shown survival benefits. Vaccines have shown little activity in stage IV disease. To advance the identification of effective agents, new drugs can and should be offered as first-line treatment. Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs.",

author = "Eggermont, {Alexander M.M.}",

year = "2006",

month = apr,

doi = "10.1016/j.soc.2005.12.001",

language = "English",

volume = "15",

pages = "439--451",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Randomized Trials in Melanoma

T2 - An Update

AU - Eggermont, Alexander M.M.

PY - 2006/4

Y1 - 2006/4

N2 - No effective therapy for metastatic melanoma exists. Polychemotherapy or chemoimmunotherapy have not shown survival benefits. Vaccines have shown little activity in stage IV disease. To advance the identification of effective agents, new drugs can and should be offered as first-line treatment. Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs.

AB - No effective therapy for metastatic melanoma exists. Polychemotherapy or chemoimmunotherapy have not shown survival benefits. Vaccines have shown little activity in stage IV disease. To advance the identification of effective agents, new drugs can and should be offered as first-line treatment. Efforts must be made to improve understanding of the biology of malignant melanoma. Too many phase III trials have been conducted with a poor understanding of the mechanism of action of the involved drugs.

UR - http://www.scopus.com/inward/record.url?scp=33745590474&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2005.12.001

DO - 10.1016/j.soc.2005.12.001

M3 - Review article

C2 - 16632225

AN - SCOPUS:33745590474

SN - 1055-3207

VL - 15

SP - 439

EP - 451

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

IS - 2

ER -

Randomized Trials in Melanoma: An Update

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit